Bausch + Lomb
Focus: Bausch + Lomb is a public specialty pharma company headquartered in New Jersey with a dominant focus on ophthalmology therapeutics and devices. The company derives 50% of revenue from its flagship dry eye drug XIIDRA, positioning it as a specialized player in the eye care market.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Bausch + Lomb
AI assessmentNot HiringNo open roles listed right now. Follow Bausch + Lomb to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bausch + Lomb's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthWatch
Pipeline
Early-stage
50 total
LOE Risk
1 imminent
COLAZAL
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$473MStable
Peak7.1yr
Flagship product representing 50% of company revenue; lymphocyte function-associated antigen antagonist with stable peak-stage commercial performance and extended patent protection through 2033.
Help build intelligence for Bausch + Lomb
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.